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Caregiver Health- Related Quality of 
Life, Burden, and Patient Outcomes in 
Ambulatory Advanced Heart Failure: A 
Report From REVIVAL
Nisha A. Gilotra , MD; Salpy V. Pamboukian, MD, MSPH; Maria Mountis, DO; Shawn W. Robinson, MD; 
Michelle Kittleson , MD, PhD; Keyur B. Shah, MD; Rhondalyn C. Forde- McLean, MD, MHS;  
Donald C. Haas, MD; Douglas A. Horstmanshof, MD; Ulrich P. Jorde , MD; Stuart D. Russell, MD;  
Wendy C. Taddei- Peters, PhD; Neal Jeffries, PhD; Shokoufeh Khalatbari, MS; Catherine A. Spino, ScD;  
Blair Richards, MPH; Matheos Yosef, PhD; Douglas L. Mann , MD, PhD; Garrick C. Stewart, MD, MPH;  
Keith D. Aaronson , MD, MS; Kathleen L. Grady , PhD
BACKGROUND: Heart failure (HF) imposes significant burden on patients and caregivers. Longitudinal data on caregiver health- 
related quality of life (HRQOL) and burden in ambulatory advanced HF are limited.
METHODS AND RESULTS: Ambulatory patients with advanced HF (n=400) and their participating caregivers (n=95) enrolled in 
REVIVAL (Registry Evaluation of Vital Information for VADs [Ventricular Assist Devices] in Ambulatory Life) were followed up for 
24 months, or until patient death, left ventricular assist device implantation, heart transplantation, or loss to follow- up. Caregiver 
HRQOL (EuroQol Visual Analog Scale) and burden (Oberst Caregiving Burden Scale) did not change significantly from base-
line to follow- up. At time of caregiver enrollment, better patient HRQOL by Kansas City Cardiomyopathy Questionnaire was 
associated with better caregiver HRQOL (P=0.007) and less burden by both time spent (P<0.0001) and difficulty (P=0.0007) 
of caregiving tasks. On longitudinal analyses adjusted for baseline values, better patient HRQOL (P=0.034) and being a mar-
ried caregiver (P=0.016) were independently associated with better caregiver HRQOL. Patients with participating caregivers 
(versus without) were more likely to prefer left ventricular assist device therapy over time (odds ratio, 1.43; 95% CI, 1.03– 1.99; 
P=0.034). Among patients with participating caregivers, those with nonmarried (versus married) caregivers were at higher 
composite risk of HF hospitalization, death, heart transplantation or left ventricular assist device implantation (hazard ratio, 
2.99; 95% CI, 1.29– 6.96; P=0.011).
CONCLUSIONS: Patient and caregiver characteristics may impact their HRQOL and other health outcomes over time. 
Understanding the patient- caregiver relationship may better inform medical decision making and outcomes in ambulatory 
advanced HF.
Key Words: caregiving ■ heart failure ■ left ventricular assist device ■ quality of life
Heart failure (HF) is a time intensive chronic condi-tion heavily reliant on self- care to maintain health and manage symptoms of congestion, thus im-
posing significant burden on patients and their care-
givers.1– 3 Caregivers play a critical role in daily HF 
disease management tasks, as well as logistical sup-
port for care coordination, emotional support, and par-
ticipation in complex medical decision making.4,5 As 
HF progresses, patients often become more reliant on 
caregivers, who may experience an increased sense 
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of burden as support needs increase6 or change in 
health- related quality of life (HRQOL).7 In addition, as 
has been shown in qualitative analyses of caregivers, 
patient decisions about HF treatment preferences may 
be impacted by caregiver understanding of disease.8 
The HF caregiver’s role has become increasingly com-
plex with advances in medical and surgical treatments 
for HF, as acknowledged by a recent American Heart 
Association Scientific Statement on family caregiving 
in HF.9
Existing studies of patients with HF and their care-
givers have focused primarily on caregivers of pa-
tients undergoing advanced HF therapies, such as left 
ventricular assist device (LVAD) implantation or heart 
transplantation.10– 12 Despite a recognized association 
between caregiver HRQOL and patient outcomes, lon-
gitudinal data on burden and HRQOL for caregivers of 
patients with advanced HF are lacking.13 Furthermore, 
to our knowledge, burden and HRQOL have not been 
examined in caregivers of ambulatory patients with 
advanced HF. REVIVAL (Registry Evaluation of Vital 
Information for VADs [Ventricular Assist Devices] in 
Ambulatory Life) provides an opportunity to study 
caregiver burden and HRQOL over time in an ambula-
tory advanced HF cohort. The purposes of our report 
from REVIVAL are to: (1) examine change in caregiver 
HRQOL and burden over time compared with patient 
HRQOL, (2) identify patient and caregiver factors re-
lated to caregiver HRQOL and burden, and (3) exam-
ine whether caregiver factors are related to patient 
HRQOL, preference for LVAD therapy, and clinical out-
comes. We hypothesized that (1) advanced HF patient 
HRQOL and caregiver HRQOL will decline over time, 
whereas caregiver burden will increase over time, (2) 
both caregiver characteristics (eg, high perceived bur-
den) and patient characteristics (eg, poor HRQOL) will 
be related to caregiver HRQOL, whereas patient char-
acteristics (eg, worse HF and worse patient HRQOL) 
will be related to increased caregiver burden, and (3) 
caregiver characteristics (eg, being a spouse or part-
ner) will be related to patient preference for LVAD ther-
apy and patient clinical outcomes.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request.
Study Population
REVIVAL is a prospective, observational, multicenter 
cohort of ambulatory patients with advanced HF that 
also includes caregivers.14 Patients and caregivers 
were enrolled from 21 centers between July 2015 
and June 2016. Patients enrolled were aged 18 to 
80 years with New York Heart Association functional 
class II to IV limitations for at least 45 of the previous 
60 days, left ventricular ejection fraction ≤35%, and a 
HF diagnosis >12 months. All patients were on maxi-
mum tolerated doses of evidence- based HF medical 
and electrical therapies for ≥3 months or had a docu-
mented contraindication or intolerance to medication 
use. In addition, enrollment required subjects to have 
1 high- risk feature for mortality (ie, reduced peak oxy-
gen uptake, reduced 6- minute walk distance, elevated 
CLINICAL PERSPECTIVE
What Is New?
• In an ambulatory cohort of patients with ad-
vanced heart failure, we found that surviving 
patients’ health- related quality of life improved 
modestly over time and that caregivers’ health- 
related quality of life and burden did not change.
• Having a participating, married caregiver was 
associated with an increased patient willing-
ness to consider ambulatory left ventricular as-
sist device therapy and a lower composite risk 
of death, urgent transplant, or left ventricular as-
sist device therapy.
What Are the Clinical Implications?
• Caregivers play a fundamental role in the lives of 
patients with advanced heart failure; however, 
their impact on clinical outcomes is not com-
monly considered.
• These data highlight the need for including 
caregiver perspective and presence when as-
sessing patient longitudinal outcomes and 
understanding shared decision making in ad-
vanced heart failure.
• Efforts are needed to increase caregiver par-
ticipation in clinical studies to better understand 
the important role of the caregiver in heart 
failure.
Nonstandard Abbreviations and Acronyms
EQ- VAS EuroQol Visual Analog Scale
INTERMACS Interagency Registry for 
Mechanically Assisted Circulatory 
Support
KCCQ Kansas City Cardiomyopathy 
Questionnaire
OCBS Oberst Caregiving Burden Scale
REVIVAL Registry Evaluation of Vital 
Information for VADs (Ventricular 
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natriuretic peptide level, reduced serum sodium, de-
creased Seattle Heart Failure Model 1- year predicted 
survival, or active United Network for Organ Sharing 
status 2 heart transplant), 1 unplanned HF hospitali-
zation in the prior 12 months with a lesser threshold 
for natriuretic peptide level, or 2 unplanned HF hos-
pitalizations in the prior 12  months (Tables S1 and 
S2). Patient participants were enrolled in REVIVAL at 
the initial baseline A visit, and caregivers were sub-
sequently identified and enrolled at the baseline B 
visit (≈2  months later). Patients were determined to 
have participating caregivers if the patient com-
pleted a baseline B visit and a caregiver was enrolled 
at that visit with completion of at least one baseline 
HRQOL survey. An independent Observational Study 
Monitoring Board oversaw the conduct of REVIVAL. 
The Institutional Review Board at each center ap-
proved the study. All subjects (patients and caregiv-
ers) provided written informed consent before study 
participation.
Data Collection and Outcomes
Patients were followed up for 24  months or until 
earlier death, heart transplantation, or implantation 
of durable mechanical circulatory support. Clinical 
evaluation occurred at enrollment (baseline A), and at 
2 (baseline B), 6, 12, 18, and 24 months. The follow-
ing data were collected for patients at the baseline B 
visit: demographics, clinical characteristics, medica-
tions, laboratory values, physical examination results, 
and a 6- minute walk test. INTERMACS (Interagency 
Registry for Mechanically Assisted Circulatory 
Support) patient profiles were assigned at each visit 
by the treating cardiologist, according to methods 
previously described.15 Outcomes prospectively col-
lected at the time of occurrence included hospitali-
zations, heart transplantation, mechanical circulatory 
support, and death. At study entry and each visit, 
patients were asked to read a 2- page document con-
taining a basic description and illustration of an LVAD, 
along with information about indications, benefits, 
and complications of LVAD therapy.16 The description 
of LVAD therapy was written at a US eighth- grade 
education level (Flesch- Kincaid readability ease). The 
probabilities of survival, recurrent hospitalization, and 
adverse events following LVAD included in the instru-
ment were based on event rates of approved devices 
at the time of survey development in 2015. Subjects 
were then asked to reply on a Likert- type scale to 
the question: “Based on how you feel right now, how 
would you feel about having a VAD placed to treat 
your heart failure?” Subjects were classified into 3 
groups based on their responses: (1) wanting LVAD 
(including “definitely want” and “probably want”), 
(2) unsure, and (3) not wanting LVAD (including 
“probably not want” and “definitely not want”). Other 
self- report instruments were administered as follows: 
patients (at study entry [baseline A] and at 2 [baseline 
B], 6, 12, 18, and 24 months) and caregivers (at study 
entry at 2 months [baseline B], and at 6, 12, 18, and 
24 months).
HRQOL and Burden Instruments
At each visit, patients were asked to complete 
(via self- report) 2 validated HRQOL instruments, 
the Kansas City Cardiomyopathy Questionnaire 
(KCCQ)17 and EuroQol Visual Analog Scale (EQ- 
VAS).18 The KCCQ, an HF- specific tool, consists 
of 23 multiple- choice questions with 7 domains: 
Physical Limitations (6 items), Symptom Stability 
(1 item), Symptom Frequency (4 items), Symptom 
Burden (3 items), Self- Efficacy (2 items), Quality of 
Life (3 items), and Social Limitations (4 items). The 
Overall Summary Score is calculated as an average 
of the Physical Limitations, Total Symptoms, Quality 
of Life, and Social Limitations scores.17 Higher scores 
(range, 0– 100) reflect fewer limitations, lower symp-
tom frequency and burden, and better HRQOL. The 
EQ- VAS score measures self- rated overall health 
(range, 0– 100) wherein end points are labeled “best 
imaginable health state” (higher score) and “worst 
imaginable health state” (lower score). An EQ- VAS 
score <55 has been considered to represent poor 
HRQOL in ambulatory advanced HF, and was thus 
used as a measure of HRQOL in this study.19 Prior 
studies have considered clinically important changes 
in score on the KCCQ and EQ- VAS to be 5 and 10 
points, respectively.20,21 At enrollment, patients were 
also administered the Personal Health Questionnaire, 
an 8- question validated measure that screens for de-
pression.22 Caregivers also completed the EQ- VAS. 
In addition, caregiver burden was assessed using the 
validated Oberst Caregiving Burden Scale (OCBS), 
which measures 15 caregiving physical and emo-
tional tasks in 2 domains (time spent on task and 
difficulty of task) using 5- point Likert scales: for time: 
1=none to 5=a great amount of time; and for diffi-
culty: 1=not difficult to 5=extremely difficult.23
Statistical Analysis
Both patient and caregiver demographic and clini-
cal characteristics were summarized as counts and 
percentages for categorical data and median and 
interquartile range (IQR) for continuous data. Patient 
characteristics were compared between groups with 
and without participating caregivers using χ2 tests 
for categorical data and Wilcoxon rank- sum tests for 
continuous data. Linear mixed model analyses of pa-
tient HRQOL (EQ- VAS and KCCQ) as well as caregiver 
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and difficulty) were performed, with time (study visits) 
as a continuous variable (visits number 1 [baseline A] 
to 6 [month 24]) and with adjustment for baseline val-
ues, to assess their longitudinal effects. The analyses 
of patient HRQOL were performed with (1) all enrolled 
patients (n=400), (2) patients who completed a base-
line B visit (n=337) as these were the patients eligi-
ble for caregiver enrollment, or (3) the subset of those 
patients with a participating caregiver (n=95) as indi-
cated. For the purposes of the longitudinal HRQOL 
analysis of patients, patient baseline instrument score 
(ie, KCCQ or EQ- VAS) was considered that obtained 
at patient enrollment (baseline A visit), whereas for 
caregiver analyses, patient baseline scores were con-
sidered those obtained at time of caregiver enrollment 
(baseline B visit). Univariable and multivariable linear 
mixed model analyses of caregiver EQ- VAS scores 
were conducted with patient and caregiver charac-
teristics as predictors. Cross- sectional (at baseline B) 
effects of patient and caregiver characteristics on car-
egiver HRQOL and caregiver burden were assessed 
using univariable and multivariable regression analy-
ses. The following patient characteristics were in-
cluded as predictors based on known contributions to 
patient severity of illness and patient- caregiver relation-
ship: EQ- VAS, KCCQ, frailty, gait speed, and Seattle 
Heart Failure Model score. Caregiver characteristics 
included: relationship to patient (versus spouse/do-
mestic partner), paid employment, educational level 
(versus less than high school), number of surgeries, 
female sex, race (White compared to nonWhite race), 
and marital status. Univariable and multivariable linear 
mixed model analyses of patient HRQOL were con-
ducted with caregiver characteristics as predictors: 
educational level, female sex, marital status, EQ- VAS, 
and OCBS time and difficulty scores.
Univariable repeated measures logistic regression 
analysis was performed to assess which caregiver 
baseline characteristics were related to patient prefer-
ence for LVAD therapy. To this end, the 5- level patient 
preference for LVAD therapy was dichotomized into 
“yes, I want an LVAD placed to treat my HF” (from cat-
egories: definitely and probably want) and “no, I don’t 
want an LVAD” (from categories: “not sure,” “definitely 
not,” and “probably not”). The composite clinical out-
come included the following patient outcomes, which 
were combined for analysis because of low numbers 
of individual events: first unplanned HF- related hos-
pitalization, heart transplantation, durable mechan-
ical circulatory support, and death. Univariable and 
multivariable linear mixed model analyses of patient 
HRQOL (EQ- VAS and KCCQ) and Cox regression 
analysis of time to the composite outcome were per-
formed to ascertain which caregiver baseline char-
acteristics were related to these patient outcomes. 
The corresponding multivariable analyses of these 3 
patient outcomes (ie, generalized linear mixed model 
analyses of patient preference for LVAD therapy and 
linear mixed model analyses of patient HRQOL as well 
as Cox regression analysis of time to the composite 
outcome) were also performed versus caregiver par-
ticipation, INTERMACS profile, and their interactions. 
In the latter case, a time trend term for INTERMACS 
was included in the model because of failure of the 
hazard proportionality assumption. To assess poten-
tial bias resulting from missing caregiver data, Fisher 
exact and 2- sample Wilcoxon tests were used to 
compare selected categorical and continuous patient 
and caregiver characteristics between the groups 
with missing and nonmissing caregiver HRQOL and 
burden data, respectively. To further assess survi-
vorship bias and the potential effects of missing data 
on HRQOL and burden assessments, we used the 
Wilcoxon rank- sum test to compare differences in 
baseline HRQOL (patients and caregivers) and burden 
(caregivers) between those patients who did and did 
not meet any study end point.
Characteristics with P<0.15 in all above univariable 
analyses were entered into the corresponding step-
wise multivariable analyses, and those variables with 
P<0.05 were considered statistically significant in the 
final multivariable models. No adjustments were made 
for multiple hypotheses testing. Analyses were per-
formed using SAS version 9.4 (Cary, NC).
RESULTS
Study Cohort
A total of 400 patients with ambulatory advanced 
HF were enrolled in REVIVAL. Over the length of the 
REVIVAL study, 61 subjects died, 57 subjects received 
a durable LVAD, and 30 subjects underwent heart 
transplantation (23 as a United Network for Organ 
Sharing status 1A or 1B and 7 as a status 2). Of the 400 
patients, 337 completed a baseline B visit, of which 95 
had participating caregivers. The clinical outcomes of 
subjects based on whether they completed baseline B 
visits are depicted in Figure 1.
Table  1 describes baseline characteristics of pa-
tients with (n=95) and without (n=242) participating 
caregivers. Patients with participating caregivers were 
more frequently older and White race, and more had 
a postgraduate degree, compared with those without 
participating caregivers. There were no differences in 
HF severity based on INTERMACS profile, New York 
Heart Association functional class, or Seattle Heart 
Failure Model score. Participating caregivers (n=95) 
were mostly women, White race, and the spouse or 
domestic partner of the patient (Table 2).
Forty- three caregivers did not have end of study 
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reasons: 15 patients died, 8 patients received an 
LVAD, 4 patients withdrew consent, 3 caregivers 
were withdrawn because of investigator withdrawal 
of study subject, 1 caregiver withdrew consent (while 
the patient remained in study), and 12 were otherwise 
lost to follow- up for unknown reasons. Differences in 
patient and caregiver baseline characteristics based 
on caregiver missingness at 24 months are presented 
in Table S3. Patients with missing caregiver HRQOL 
and burden data were significantly younger than those 
without missing caregiver data. There were more fe-
male caregivers in the missing group compared with 
the nonmissing group. There were no differences in 
baseline HRQOL (patients or caregivers) and burden 
(caregivers) scores based on whether patients experi-
enced the composite study end point (death, durable 
Figure 1. REVIVAL (Registry Evaluation of Vital Information for VADs [Ventricular Assist Devices] in Ambulatory Life) 
enrollment flowchart.
*Caregivers who signed informed consent and completed at least one baseline quality- of- life survey. INTERMACS indicates Interagency 
Registry for Mechanically Assisted Circulatory Support; MCS, mechanical circulatory support; TXP, transplant; and UNOS, United 
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Age, y 61 (52 to 67) 64 (57 to 71) 62 (54 to 68) 0.004*
Sex
Women 67 (27.7) 19 (20) 86 (25.5) 0.15
Men 175 (72.3) 76 (80) 251 (74.5)
Race
Black 69 (28.5) 10 (10.5) 79 (23.4) 0.0001*
White 155 (64.0) 83 (87.4) 238 (70.6)
Other 18 (7.4) 2 (2.1) 20 (5.9)
Ethnicity
Hispanic or Latino 26 (10.7) 2 (2.1) 28 (8.3) 0.006*
Non- Hispanic or non- Latino 208 (86) 93 (97.9) 301 (89.3)
Unknown/undisclosed 8 (3.3) 0 (0) 8 (2.4)
Education
Grade school (grades 1– 8) 8 (3.3) 0 (0) 8 (2.4) 0.035*
High school 65 (26.9) 26 (27.4) 91 (27)
Attended college/technical school 60 (24.8) 28 (29.5) 88 (26.1)
Associate degree 17 (7.0) 7 (7.4) 24 (7.1)
Bachelor degree 30 (12.4) 11 (11.6) 41 (12.2)
Postgraduate degree 13 (5.4) 13 (13.7) 26 (7.7)
Unknown 49 (20.2) 10 (10.5) 59 (17.5)
Ischemic cardiomyopathy 104 (43.0) 43 (45.3) 147 (43.6) 0.70
Diabetes mellitus (n=336) 91 (37.8) 34 (35.8) 125 (37.2) 0.74
Atrial fibrillation (n=331) 92 (39.0) 40 (42.1) 132 (39.9) 0.6
Heart failure diagnosis >5 y 134 (55.4) 56 (58.9) 190 (56.4) 0.55
Frailty (n=284)
Not frail 94 (48.2) 39 (43.8) 133 (46.8) 0.02*
Prefrail 61 (31.3) 41 (46.1) 102 (35.9)
Frail 40 (20.5) 9 (10.1) 49 (17.3)
NYHA class
I 7 (2.9) 4 (4.2) 11 (3.3) 0.73
II 84 (34.7) 28 (29.5) 112 (33.2)
III 117 (48.3) 52 (54.7) 169 (50.1)
IIIb 22 (9.1) 8 (8.4) 30 (8.9)
IV 12 (5) 3 (3.2) 15 (4.5)
INTERMACS profile
2 1 (0.4) 0 (0) 1 (0.3) 0.40
3 1 (0.4) 2 (2.1) 3 (0.9)
4 21 (8.7) 6 (6.3) 27 (8)
5 44 (18.2) 24 (25.3) 68 (20.2)
6 78 (32.2) 29 (30.5) 107 (31.8)
7 97 (40.1) 34 (35.8) 131 (38.9)
PHQ ≥10 (+depression screen) (n=306) 53 (24.8) 22 (23.9) 75 (24.5) 0.87
Left ventricular ejection fraction (n=319) 28.08 (23 to 33.4) 29.0 (23.2 to 33) 28.5 (23 to 33.4) 0.87
6- MWD, m (n=299) 361.4 (280 to 416) 364.2 (300.2 to 417) 362.7 (292.6 to 417) 0.89
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mechanical circulatory support, or heart transplanta-
tion) (Table S4).
Patient and Caregiver HRQOL and Burden 
Over Time
When examining the baseline A patient cohort (n=400), 
patient HRQOL, as measured using the EQ- VAS score 
and KCCQ Overall Summary Score, demonstrated 
improvement over time. At baseline A (patient enroll-
ment), the median patient EQ- VAS score was 65 (IQR, 
50– 75) and KCCQ score was 64 (IQR, 48– 78). By the 
24- month visit, the patient KCCQ score increased by 
a median of 3 points (IQR, −7 to 13 points), whereas 
the EQ- VAS score increased by a median of 5 points 
(IQR, −5 to 17 points). In a linear mixed model adjusting 
for scores at time of patient enrollment, both EQ- VAS 
scores (estimate, 0.88; 95% CI, 0.44– 1.32; P<0.0001) 
and KCCQ score (estimate, 0.49; 95% CI, 0.13– 0.84; 
P=0.007) increased significantly, demonstrating longi-
tudinal improvement in HRQOL that was dependent on 
baseline values. This result remained significant when 
further adjusted for INTERMACS profile (Table 3). We 
repeated the above analysis for those patients (n=337) 
completing a baseline B visit, the visit at which car-
egivers were enrolled, and found similar results. When 
adjusted for INTERMACS profile, both patient EQ- VAS 
(P=0.0006) and KCCQ (P=0.016) scores improved 
over time (Table 3).
Participating caregivers’ overall HRQOL (EQ- 
VAS) and burden (OCBS) were assessed at base-
line B and follow- up. Baseline caregiver median 
EQ- VAS was 90 (IQR, 76– 90). Baseline caregiver 
OCBS scores for each of the 15 items addressing 
time on task and difficulty of task are described in 
Figure S1. The 3 items with the most time spent on 
tasks were emotional support, providing transpor-
tation or “company,” and watching for/monitoring 
symptoms and progress. The tasks identified as 
most difficult were managing finances/forms re-
lated to illness, performing additional household 
tasks for the patient, and managing patient be-
havior problems. Although OCBS scores did not 
change significantly from baseline to end of study 
(Figure 2), caregivers scored “time spent on tasks” 
higher than they scored “difficulty of tasks” at both 
time points. Median change in caregiver instrument 
scores from baseline to 24- month follow- up among 
those 51 caregivers with these data available were 









BMI, kg/m2 29.5 (25.3 to 35.1) 28.5 (25.2 to 33.4) 29.1 (25.3 to 34.4) 0.68
EQ- VAS score(n=305) 70 (50 to 80) 70 (50 to 80) 70 (50 to 80) 0.78
KCCQ (n=308) 66 (51 to 81) 63 (43 to 77) 66 (48 to 80) 0.26
Seattle Heart Failure Model score 0.45 (−0.2 to 1.1) 0.7 (−0.3 to 1.2) 0.5 (−0.2 to 1.2) 0.43
Number (percentage) and χ2 P values are given for categorical characteristics, and median (interquartile range) and Wilcoxon rank- sum P values are given 
for continuous characteristics. 6- MWD indicates 6- minute walk distance; BMI, body mass index; EQ- VAS, EuroQol Visual Analog Scale (range, 0 [worst health 
state] to 100 [best health state]); INTERMACS, Interagency Registry for Mechanically Assisted Circulatory Support; KCCQ, Kansas City Cardiomyopathy 
Questionnaire overall summary score (range, 1 [worse] to 100 [better]); NYHA, New York Heart Association; and PHQ, personal health questionnaire.
*Significant P value < 0.05.
Table 1. Continued
Table 2. Baseline Characteristics of Participating 
Caregivers
Characteristic Value









Spouse/domestic partner 72 (76.6)
Son/daughter 8 (8.5)









Oberst Caregiver Burden Scale
Time spent average score 2.2 (1.7– 2.8)
Difficulty average score 1.1 (1– 1.5)
Data are given as number (percentage) for categorical characteristics and 
median (interquartile range) for continuous characteristics. Oberst Caregiver 
Burden Scale time spent on task: 1=none to 5=a great amount of time; and 
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OCBS time score, 0 (IQR, −0.33 to 0.33; P=0.93); 
and mean OCBS difficulty score, 0 (IQR, −0.2 to 
0.23; P=0.58). Caregiver overall HRQOL and burden 
did not demonstrate change over time in a linear 
mixed model with time as a continuous variable and 
with adjustment for baseline scores (Table 4).
Baseline Characteristics Related to 
Caregiver HRQOL
In cross- sectional analysis at the time of caregiver en-
rollment (baseline B visit), a higher patient KCCQ over-
all summary score was significantly associated with a 
higher caregiver EQ- VAS score (estimate, 0.18; 95% 
CI, 0.05– 0.31; P=0.007), less caregiver OCBS time (es-
timate, −0.02; 95% CI, −0.02 to −0.01; P<0.0001), and 
less caregiver OCBS difficulty (estimate, −0.01; 95% 
CI, −0.01 to −0.004; P=0.0007).
In the longitudinal multivariable analysis of pa-
tient and caregiver characteristics on the outcome 
of caregiver overall HRQOL, adjusted for the base-
line caregiver EQ- VAS score, a higher patient time- 
dependent KCCQ overall summary score (estimate, 
0.10; 95% CI, 0.01– 0.19; P=0.034) and being a mar-
ried caregiver (estimate, 7.05; 95% CI, 1.34– 12.8; 
P=0.016) were independently associated with higher 
caregiver overall HRQOL (Table 5). Of note, of the 82 
caregivers who were married, 72 were spouses of 
the patient.
Caregiver Characteristics Related to 
Patient HRQOL and Outcomes Over Time
In the multivariable analysis, higher patient EQ- VAS 
scores were associated with higher caregiver EQ- VAS 
scores over time (estimate, 0.26; 95% CI, 0.15– 0.37; 
P<0.0001), whereas lower patient EQ- VAS scores were 
significantly related to higher caregiver mean OCBS 
time scores (estimate, −5.43; 95% CI, −8.25 to −2.62; 
P=0.0002). Similarly, worse patient KCCQ overall sum-
mary scores were correlated with higher caregiver 
mean OCBS time scores (estimate, −10.6; 95% CI, 
−13.3 to −7.8; P<0.0001).
Factors Related to Patient Preferences 
for LVAD Therapy and Composite Patient 
Clinical Outcomes
Patients with participating caregivers (versus without) 
had a higher odds of a “yes” response for preference 
for LVAD therapy over time (odds ratio, 1.43; 95% CI, 
1.03– 1.99; P=0.034), adjusted for time- dependent 
Figure 2. Caregiver mean time (n=51) and difficulty (n=52) summary scores at baseline (black 
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INTERMACS profile (P>0.05). Of those with a partici-
pating caregiver, 5 of 32 (16%) patients who had an 
initial preference of “yes” for LVAD underwent LVAD 
implantation during study follow- up (additional 2 were 
transplanted), whereas 8 of 59 (14%) of those saying 
“no” underwent LVAD (additional 2 were transplanted). 
For patients with a participating caregiver, the risk of 
experiencing the composite clinical outcome event 
(first unplanned HF- related hospitalization, heart trans-
plantation, LVAD placement, or death) was assessed in 
a multivariable Cox proportional hazard model includ-
ing INTERMACS profile and baseline participating car-
egiver characteristics. Both worsening INTERMACS 
profile (hazard ratio [HR], 1.52; 95% CI, 1.13– 2.04; 
P=0.005) and having a nonmarried participating car-
egiver (HR, 2.99; 95% CI, 1.29– 6.96; P=0.011) sig-
nificantly increased the hazard of a patient having an 
event.
DISCUSSION
Among ambulatory patients with advanced HF, we 
determined that: (1) patient HRQOL improved over 
time when adjusted for the baseline value, whereas 
participating caregiver HRQOL and burden did not, 
contrary to our hypothesis that these would worsen 
over time; (2) caregiver HRQOL and burden were 
positively associated with patient HRQOL, as hy-
pothesized; and (3) having a participating caregiver 
increased likelihood of patient preference for LVAD 
therapy, whereas having a nonmarried participating 
caregiver increased the risk of having a clinical 
event. Although HRQOL in patients with HF and 
cross- sectional caregiver HRQOL are well char-
acterized in the literature, we describe, for the first 
time, longitudinal HRQOL and burden of caregivers 
of an ambulatory cohort of patients with advanced 
HF.
Patient HRQOL
Patients with HF have poor HRQOL when compared 
with those without HF.24 More important, HRQOL is 
associated with other HF- related outcomes, with 
improvement in HRQOL being associated with bet-
ter event- free survival.25 In our overall cohort of am-
bulatory patients with advanced HF, we found that 
patient HRQOL significantly improved over time 
among survivors when adjusted for baseline val-
ues by both the KCCQ and the EQ- VAS. Change 
in patient HRQOL is linked to comorbidities26 as 
well as HF symptom severity.27 Our study corrob-
orates these prior findings as we showed that the 
less severe the INTERMACS profile, the better the 
patient HRQOL. When adjusted for INTERMACS 
profile and presence of a caregiver, EQ- VAS scores 
continued to improve over time, whereas KCCQ 
overall summary scores did not. This may be attrib-
utable to differences in the measures (ie, the EQ- 
VAS is a generic instrument, whereas the KCCQ is 
an HF- specific instrument). Also, the EQ- VAS is a 
single item measuring overall HRQOL, whereas the 
KCCQ overall summary score is derived from mul-
tiple items and domains. More important, although 
change over time was seen in the KCCQ (median 
increase, 3 points) and EQ- VAS (median increase, 5 
points), these changes were small relative to what is 
considered a minimal clinically important difference 
in these scores (5 and 10 points, respectively).20,21 
However, the lack of either clinically or statisti-
cally significant deterioration in these measures of 
HRQOL in survivors over the 2- year course of the 
study is also notable.
Table 4. Longitudinal Model of Caregiver HRQOL (Measured Using EQ- VAS) and Burden (Measured Using OCBS) Over 
Time, Adjusted for Baseline Values
Variable
EQ- VAS OCBS Mean Difficulty OCBS Mean Time
Estimate  
(95% CI) P Value
Estimate  
(95% CI) P Value
Estimate  
(95% CI) P Value
EQ- VAS, baseline 0.64 (0.49 to 0.79 ) <0.0001*
OCBS mean difficulty, 
baseline
0.72 ( 0.63 to 0.82) <0.0001*
OCBS mean time, 
baseline
0.74 ( 0.64 to 0.84) <0.0001*
Time 0.003 (−1.12 to 1.12 ) 0.996 0.019 (−0.01 to 0.05) 0.179 −0.0004 (−0.04 to 0.04 ) 0.985
EQ- VAS indicates EuroQol Visual Analog Scale; HRQOL, health- related quality of life; and OCBS, Oberst Caregiver Burden Scale.
*Significant P value < 0.05.
Table 5. Longitudinal Analysis of Caregiver HRQOL Over 
Time, Adjusted for Baseline Values
Variable Estimate (95% CI) P Value
Caregiver EQ- VAS 0.61 (0.45– 0.77) <0.0001
Patient KCCQ 0.10 (0.01– 0.19) 0.034
Caregiver marital status 7.05 (1.34– 12.80) 0.016
EQ- VAS indicates EuroQol Visual Analog Scale; HRQOL, health- related 
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Caregiver Burden and HRQOL
Caregivers play a fundamental role in the care of 
patients with HF, including personal and emotional 
care.2,28 Increased caregiver burden is associated 
with poor health outcomes for caregivers and patients 
alike,6,29 although interestingly, results of prior stud-
ies have also demonstrated an association between 
higher caregiver burden and lower patient clinical event 
risk.30 In our study, using the OCBS, caregivers expe-
rienced higher burden with time spent rather than dif-
ficulty of tasks, with time providing emotional support 
being highest. The latter finding has been reported in 
other studies of caregiving in HF.7 Caregiver burden 
did not increase over time, contrary to our hypothesis 
that caregiver burden increases over time in patients 
with advanced stages of HF. Pressler and colleagues 
demonstrated in a general ambulatory HF cohort (with 
10% loss to follow- up attributable to death/severity of 
illness) that caregiver burden, also measured using 
the OCBS, actually improved over a 9- year period.7 In 
Pressler’s study, the Medical Outcomes Study Short 
Form- 12 was used to demonstrate lack of worsening 
in caregiver HRQOL. We also did not find a significant 
decline in caregiver HRQOL using the EQ- VAS.
Potential explanations for our findings that caregiver 
HRQOL and burden did not worsen over time include: 
(1) REVIVAL was composed of a HF cohort that, based 
on inclusion criteria, already had medically advanced 
disease at time of patient and caregiver enrollment; (2) 
there was a survivorship effect, with loss of follow- up 
data on a substantial proportion of sicker patients 
who went on to meet clinical end points (although one 
would still have expected deterioration of clinical sta-
tus, including quality of life, among survivors), which 
decreased caregiver participation over time; and (3) 
caregivers may not perceive their care for patients as 
burdensome or may adapt over time to caregiving re-
lated tasks, making the perceived burden low and un-
changing, which may also impact caregiver HRQOL in 
a positive way.
Our study uniquely aimed to describe the effects of 
caregiver and patient baseline characteristics on overall 
caregiver HRQOL over time. Among patients with par-
ticipating caregivers, we found that caregiver HRQOL 
and burden were better when patient HRQOL was bet-
ter, at baseline and longitudinally. In the HF literature, 
better caregiver HRQOL and lower burden have been 
described for patients with less severe HF symptoms, 
which ultimately also affect patient HRQOL. Studies 
have demonstrated conflicting results on the relation-
ship of a caregiver or spouse’s HRQOL with a patient’s 
HRQOL.30,31 Our and prior findings highlight the com-
plex interdependence between patient and caregiver 
HRQOL, which may also depend on changes over time 
in patient and caregiver health status. In addition, the 
dynamic effect of patient HRQOL on caregiver HRQOL 
and vice versa most likely results in a bidirectional rela-
tionship on HRQOL over time.
We also found that caregiver HRQOL was better 
over time when caregivers were married, but not oth-
erwise associated with several caregiver characteris-
tics. The positive effect of marital status on caregiver 
HRQOL (noting that most married caregivers in our 
study were partners of the patient) deserves further 
study, as we did not measure “quality” of the marital 
relationship. Although studies to date do not describe 
health of a spouse as impacting HF outcomes in pa-
tients,31 the health of a patient with HF has been shown 
to impact the caregiving partner.32
Factors Related to Patient Clinical 
Outcomes and Preferences for LVAD 
Therapy
Patient HRQOL is associated with HF clinical out-
comes. In the nonrandomized ROADMAP (Risk 
Assessment and Comparative Effectiveness of Left 
Ventricular Assist Device and Medical Management) 
study, among subjects with worse HRQOL (EQ- VAS 
score, <55), survival on the original therapy was lower 
with medical management than with ambulatory LVAD 
therapy.19 From REVIVAL, our group has recently de-
scribed that patients with worse baseline KCCQ scores 
were more likely to prefer LVAD therapy.16,33 Therefore, 
in addition to standard clinical risk factors, patient- 
reported outcomes, such as HRQOL, should be incor-
porated into shared decision making on advanced HF 
therapies. The addition of longitudinal assessment of 
patient HRQOL in HF may lend even further insight.
We found that the presence of a participating care-
giver was the only assessed caregiver characteristic that 
was predictive of patient preference for LVAD therapy. As 
noted above, although we cannot speak to the quality of 
the caregiver- patient relationship, perhaps patients with 
participating caregivers had more engaged, supportive 
caregivers, which may have influenced their inclination 
to undergo LVAD implantation. In a recent analysis of the 
entire REVIVAL cohort, we demonstrated that patient 
socioeconomic status influenced preference for LVAD 
therapy, with patients more likely to prefer LVAD therapy 
if they had a lower income or lower education level.16 
In the present study, patients who had a participating 
caregiver were more likely to both prefer LVAD therapy 
and have a higher education level compared with pa-
tients without a participating caregiver. The reason for 
these discrepant findings on education level and LVAD 
preference are unclear and may be influenced by the 
presence of a participating caregiver. Further investiga-
tion into better understanding the interplay of socioeco-
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for advanced HF therapies is warranted. Notably, hav-
ing a nonmarried caregiver increased patient risk of 
reaching a clinical end point, independent of HF sever-
ity based on INTERMACS profile. This finding requires 
further study, as the number of nonmarried caregivers 
in our study was small and included individuals with a 
variety of relationships with the patient.
This study has several important limitations. 
Patients were recruited from centers with HF programs 
and therefore may not be representative of all patients 
with ambulatory advanced HF. Patients and caregivers 
were also enrolled at different baseline visits; patients 
were enrolled 2 months earlier than caregivers, which 
may influence outcomes and result in selection bias. 
Caregivers included in this study may not be represen-
tative of all patient caregivers who existed, for several 
reasons. First, a low proportion of REVIVAL advanced 
HF patient cohort had a participating caregiver in the 
registry, and there was dropout in caregiver participa-
tion over time. This limitation resulted in a moderately 
small caregiver sample size. Furthermore, caregivers 
lacked diversity (ie, predominantly women, White race, 
and spouses), which reduced generalizability. Lack 
of participating caregivers may reflect caregiver time 
constraints or disinterest and does not exclude the 
presence of an actively engaged caregiver. We also 
do not know about the quality of the caregiver- patient 
relationship. These limitations importantly highlight 
challenges that exist in conducting caregiver research. 
Future research to elucidate reasons for low caregiver 
participation and improve caregiver recruitment is war-
ranted. More important, the results of this study per-
tain only to patients surviving the duration of the study 
and their caregivers. The association between worse 
INTERMACS profile (ie, sicker patients) and meeting a 
clinical end point (death, transplant, or LVAD) is well 
established. Therefore, the sickest patients and their 
caregivers are missing from longitudinal HRQOL as-
sessments, which likely contributes to overestimation 
of HRQOL over time. Interestingly, we noted that fe-
male caregivers were less likely to have complete 
study data at 24 months, and a significant proportion 
of missing caregiver data was attributable to patients 
meeting clinical end points earlier in the study. One 
could hypothesize that sex differences in rates of HF 
outcomes played a role in these observed differences. 
However, notably, prior work from the REVIVAL co-
hort demonstrated that women and men had similar 
HF profiles as well as 1- year combined risk of death, 
LVAD, or transplantation (24% versus 22%; P=0.94).34
CONCLUSIONS
In an ambulatory cohort of patients with advanced HF, 
we found that surviving patients’ HRQOL improved 
modestly over time and that caregivers’ HRQOL and 
burden did not change. Having a participating, married 
caregiver was associated with an increased patient 
willingness to consider ambulatory LVAD therapy and 
a lower composite risk of death, urgent transplant, or 
ventricular assist device. These data highlight the need 
for more research on the central role of the caregiver- 
patient relationship on longitudinal outcomes and deci-
sion making in advanced HF.
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Table S1. REVIVAL Inclusion Criteria. 
1. Ambulatory.  
2. Chronic systolic heart failure ≥ 12 months. 
3. NYHA II - IV for at least 45 of the last 60 days. 
4. Last documented left ventricular ejection fraction ≤ 35% by any imaging modality. 
5. Age 18 - 80 years.  
6. Currently under the care of a cardiologist at study site. 
7. On appropriate evidenced -based heart failure medications – ACE inhibitor, ARB or 
sacubitril--valsartan; beta blocker; aldosterone antagonist; hydralazine/long-acting nitrate 
[required of African-American subjects only] for ≥ 3 months absent contraindications or 
intolerances. 
8. Has ICD or CRT-D. If CRT-D, present for ≥ 3 months.  
9. Demonstrated advanced heart failure, including any of the following*:  
i.Serum sodium ≤ 135 mEq/L (obtained as an outpatient)** 
ii.Serum BNP ≥ 750 pg/mL or NT-proBNP ≥ 3000 pg/mL** (obtained as an outpatient) 
iii.Seattle Heart Failure Model (SHFM) one year predicted survival ≤ 85%** 
iv.Heart Failure Survival Score (HFSS) ≤ 7.19** 
v.Peak VO2 ≤ 55% of predicted for age by Wasserman equation or ≤ 14 ml/kg/min, with 
RER ≥ 1.05 *** 
vi.VE/VC02 slope > 40*** 
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viii.Currently listed as Heart Transplant Status 2 due to heart failure limitation OR History 
of one (1) hospitalization (≥ 24 hours) for acute or acute on chronic heart failure in the 
past year with either serum BNP ≥ 500 pg/mL or NT-proBNP ≥ 2000 pg/mL** 
(obtained as an outpatient) 
10. History of two (2) hospitalizations (≥ 24 hours) for acute or acute on chronic heart failure in the past 
year. 
11. Willingness to continue to receive heart failure care from the enrolling advanced heart failure clinic 
over the next two (2) years and to come for all scheduled study visits. 
12. Written Informed consent given.  
 
* Qualifying measure must be the most recent of that type of measure obtained (i.e., a BNP ≥ 
1000 obtained 2 months prior would not qualify the heart failure subject if a more recent BNP 
was < 1000) 
**Using values obtained within the prior 90 days, except for peak VO2 within 365 days 
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Table S2. REVIVAL Exclusion Criteria.  
1. Known serious medical problem other than heart failure that would be expected to limit 2-
year survival (≥50% mortality within 2 years from non-heart failure diagnosis).  
2. Patient is not likely to be compliant with the protocol, in the opinion of the Investigator.  
3. Currently hospitalized. 
4. Current use of an intravenous inotrope. 
5. Primary functional limitation from non-cardiac diagnosis even if not likely to limit survival. 
6. Chronic hemodialysis or peritoneal dialysis or serum creatinine value of ≥ 3 mg/dL at time of 
enrollment. 
7. Cardiac amyloidosis, cardiac sarcoidosis, constrictive pericardial disease, active myocarditis 
or congenital heart disease with significant structural abnormality. 
8. Hypertrophic cardiomyopathy unless dilated LV and no outflow gradient. 
9. Cardiac conditions that are amenable to surgical or percutaneous procedures (other than 
VAD or transplant) that would substantially improve prognosis and for which this subject is 
a reasonable candidate, regardless of whether the procedure will or will not be performed. 
10. Uncorrected hyperthyroidism or hypothyroidism. 
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Table S3. Patient and Caregiver Baseline Characteristics by Caregiver EQ-VAS and OCBS 







Age, years 59.6 (13.2) 64.5 (10.1) 0.048 
Sex 
  Male 






14 (26.9)  
0.076 
Race   0.441 
  African-American/Black 6 (14.0) 4 (7.7)  
  White 37 (86.0) 46 (88.5)  
  Other 0 (0.0) 2 (3.8)  
New York Heart Association Class 
  I 
  II 
  III 
  IIIb 














6 minute walk distance (m) 342.5±105.2 362±88.4 0.417 
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Presence of ICD or CRT 23 (53.5) 27 (51.9) 1 
Number of heart failure 
hospitalizations  
1.00 (1.13) 0.79 (1.16) 0.246 
CAREGIVER 
Age 56.8 (16.1) 60.5 (11.9) 0.272 
Sex 
  Male 









  African-American/Black 
  White 










Relationship to patient 
  Other 
  Friend 
  Other family member 
  Son/Daughter 














Data presented as mean (SD), or counts and percentages. 
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Table S4. Baseline health-related quality of life and burden based on patient meeting study 
endpoint. 






Patient KCCQ   
(Baseline A cohort, n=400) 
64.5 (49, 80), n=242 62 (46-76), n=131 0.07 
Patient EQ-VAS  
(Baseline A cohort, n=400) 
70 (50, 75), n=238 60 (50, 75), n=129 0.16 
Patient KCCQ  
(Baseline B cohort, n=337) 
64 (49, 80), n=214 63 (48, 77), n=103 0.22 
Patient EQ-VAS 
(Baseline B cohort, n=337) 
69 (50-75), n=211 62.5 (50-75), n=102 0.55 
Caregiver EQ-VAS 
(n=95) 
85 (75, 90), n=65 90 (77.5, 94), n=32 0.39 
Caregiver OCBS, time  
(n=95) 
2.27 (1.67, 2.77), 
n=61 
2.03 (1.80, 2.83), 
n=30 
0.74 
Caregiver OCBS, difficulty 
(n=95) 
1.2 (1.00, 1.47), n=63 1.07 (1.00, 1.33), 
n=30 
0.20 
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Figure S1. Oberst Caregiving Burden Scale Scores* 
 

































5. Watching for and reporting the patient’s symptoms, watching how the patient 







6. Providing transportation or 'company' (driving, riding along with patient, 













8. Additional household tasks for the patient (laundry, cooking, cleaning, yard 







9. Additional tasks outside the home for the patient (shopping for food and 







10. Structuring/ planning activities for the patient (recreation, rest, meals, things 





















13. Communication (helping the patient with the phone, writing or reading, 







14. Coordinating, arranging, and managing services and resources for the patient 
(scheduling appointments, arranging transportation, locating equipment and 







15. Seeking information and talking with doctors, nurses, and other professional 
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